Today is information overload day for stock watchers because the 13F files of US funds have been filed and collated by the wire services. Dow Jones dumped the filings on the world. Many large cap shares were heavily traded in Q3, including many of ours. Some copycat investors are now following the announced trades today. That is another argument for small cap investing I hadn't thought of yet. But another quarter has already begun and many of the big players have reversed some of what they did in Q3. This is backward looking news.

Another thing to worry about is triple-tax free bonds in my NY muni funds besides (aie) Puerto Rico: Would you believe the US Virgins and Guam also issue municipal bonds with high yields that count as tax-free in New York? Are they safer than PR bonds?

Today we're also covering quarterly results and news from Ireland, Britain, France, the Netherlands, Brazil, Israel, Canada, Belgium, Denmark, India, and South Korea.

*The big kahuma reporting stock trades in Q3 is Steven A. Cohen who is raising money to pay a huge fine for tolerating insider trading at his SAC Capital Advisors hedge fund. Mr Cohen is trying to salvage his art collection and real estate empire by selling stocks.

Many shares we own were sold from the SAC portfolio: Alcatel Lucent (ALU), halved to $57.8 mn just about when we bought in; 78% of the stake in Liberty Media (LYTYA/K) now down to $27.9 mn; 11% of Schlumberger (SLB) down to $67.2 mn; 85% of Cosan (CZZ) and Covidien (COV.)

*Another sale by a Wall Street guru, Warren Buffett, hit one of our shares: Berkshire Hathaway sold 70% of its stake in GlaxoSmithKline, now down to a mere $17.3 mn. Janus also sold GSK down to $3.037 mn.

*Interestingly, George Soros, who runs his own private money the way Mr. Cohen will do in the future also sold ALU, one of his biggest trades. Other institutions selling Alcatel include Fidelity Asset Mgm, which also sold c40% of its prior stake in Covidien and 55% of its stake in Barrick Gold (ABX).

*COV's spinout Mallinckrodt (MNK) was bought by Paulson & Co. ($248.7 mn); and Jana Partners and O2 Management (both $78 mn). Fund managers talk to each other and sometimes can spot moves by others. Both COV and MNK are Irish.

*Major buys included Millennium buying $17 mn worth of Nokia and $32.5 mn of Teva. Janus Capital also loaded up on TEVA. We have owned both for years but sold 75% of our TEVA and only a marginal amount of our NOK.

*Kingdon Capital Management sold down Opko but bought Canadian Solar more or less what we did earlier. (We sold our Prolor to not get OPK.)

*Saneamento Basico de São Paulo (SABESP or SBS) operating revenues rose sequentially by 2.3% in Q3 to reais 2.8 bn, while costs and expenses including construction fell 2.4% to Rs 1.9 bn. As a result, SBS reported before-tax income up 15.5% to Rs833.6 mn. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA, a measure of cashflow) also rose 15.5% to Rs 1.042 bn and the EBITDA margin moved from 33.3% in Q2 to 37.6% in Q3. Net income after taxes rose 31.3% to Rs 475 mn. All in all a credible performance by SBS, the comeback kid.

*Bavarian Nordic of Denmark completed delivery of 20 mn smallpox vaccine Invamune to the US Strategic National Stockpile under a $549 mn contract. It will be used to inoculate people with compromised immune systems or skin problems, children, and pregnant women in place of standard smallpox vaccine if an emergency arises. A half year ago, the SNS ordered another 8 mn doses worth $228 mn. BVNRY will present at the Jeffereis Global Healthcare Conference in London Nov. 20.

*Galapagos, another clinical stage biotech shop, said issued a Q3 business update today, rather than a quarterly, which a Belgian traded stock is allowed to do when conditions change. Without numbers it said its Q3 met management expectations and it revised upward by euros 10 mn its target for end-2013 cash to euros 135 mn because of new business contracted with AbbVie for cystic fibrosis, and a Johnson & Johnson sub for inflammatory bowel disease, and a grant from Flemish Agency for Innovation by Science and Technology (Flanders is the part of Belgium where its Mechelen HQ is located).

These offset an end to an osteoarthritis alliance with Servier which occurred this month (in Q4) because the molecule being researched was toxic. This was the real news. The deal was replaced by a jv to seek another molecule for a novel unnamed target disease for Servier. GLPYY employs our former Italy-based biotech maven.

*GSK is building a $136 mn production plant in India to boost its emerging markets drug and consumer health businesses. Its total spending in India was about $940 mn last year. The new plant probably in Bangalore was announced by CEO Andrew Witty who was in India for a conference. It will be built by 2017

*Abhimanyu Sisodia filed today about PKX suffering from a rerun of the Park Chung-hee era in South Korea with the election of his daughter, Park Geun-hye, as president. Under her father PKX was wholly state-owned. He writes of amazing events at the 4th largest steelmaker in the world, another stock in the Berkshire Hathaway portfolio:

Posco CEO Chung Joon-yang resigned because of differences with the new Korean government which still retains significant influence. Mme Park's election aide Kim Jong-in is considered a potential replacement according to Reuters along with SK Innovation CEO Koo Ja-young. This resignation follows that of the head of another formerly state-owned company, Korea Telecom, who resigned earlier. PKX will recommend a candidate to shareholders for the Mar. annual meeting.

*Alcatel won a mandate for the world's largest mobile ultra-broadbank network from China Mobile today. The Alcatel all-IP evolved packet core internet protocol system offers data, mobility, and platform for mobile phones. ALU now has won 24% of the CM contracts out and counts as primary supplier. In Sept. it landed 11% of the CM contracts for TD-LTE base stations.

*Ambev is now trading under its 5:1 split ticker as ABEV. I put in a limit order sell but so far it has not executed. When my trade goes through, if it does, we have a new food and beverage idea to replace it.

*The beaten down fertilizer shares are up a bit today because Uralkali is expected by Bloomberg to be sold early next week. However our newest potash share, Israel Chemicals, is flat because Tel Aviv is closed on Fridays. ISCHF.

*Herzfeld Caribbean Fund (CUBA) upped its distribution by 482% from last year to $1.14/sh to be paid in shares unless you demand money. The new shares will be issued at NAV or 95% of the market price if the stock is at a discount. The distribution will take place Jan. 7 to shareholders of Dec. 6. All but one cent of the distribution is made up of long-term gains, Tom Herzfeld estimates, and the penny from short-term gains.

*Anyone who kept Global Income Fund when it opted to convert into a REIT invested in self-storage facilities should now look for SELF, not GIFD, in closed-end fund tables. Its new ticker reflects its new mandate and name, Self Storage Group. We bought it and I kept it because it was at huge discounts from NAV being traded only OTC. And because self-storage is a growth trend, but hardly part of global investing.